01 Increasing Demand for Tungsten in High-Performance Industrial and Defense Applications Tungsten is gaining strategic importance because of its exceptional hardness, density, wear resistance, and high-temperature performance. Demand is supported by cemented carbide cutting tools, mining and drilling equipment, aerospace components, defense systems, and other applications where conventional materials may not provide comparable performance. Growing industrial activity and higher defense requirements are therefore strengthening the importance of tungsten across multiple high-value applications. In March 2026, industry analysis reported that tungsten demand was being supported by aerospace, defense, energy, and tooling applications while global buyers faced increasing concerns about long-term supply reliability.
02 Accelerating Supply Chain Diversification Beyond China The tungsten market is undergoing a structural shift as manufacturers and governments seek to reduce dependence on concentrated Chinese supply. Export controls, limited mining capacity outside China, and rising strategic importance are encouraging investment in alternative mines, processing facilities, recycling systems, and supply agreements across other regions. This shift is increasing the strategic value of non-Chinese tungsten resources and reshaping global procurement strategies. In June 2026, tungsten market analysis reported that China was increasingly importing raw tungsten materials while expanding exports of higher-value processed products, contributing to greater fragmentation of international tungsten trade.
01 Expansion of Cutting, Drilling, and Wear-Resistant Applications Supports Tungsten Demand Expansion of manufacturing, infrastructure development, mining, and precision machining increases the need for durable tooling that can withstand demanding operating conditions. The broad industrial application base of tungsten carbide therefore provides a sustained foundation for tungsten consumption.
01 High and Volatile Tungsten Prices Increase Material Costs for Manufacturers Limited primary supply, concentrated production, export restrictions, and strong strategic demand can create substantial price volatility in tungsten markets. Higher raw-material costs can increase expenses for producers of tungsten carbide, alloys, tools, and other downstream products. Manufacturers operating in price-sensitive applications may therefore face pressure to improve material efficiency, increase recycling, or evaluate alternative materials where technical requirements permit.
01 Expansion of Medical and Radiation-Shielding Applications Creates New Tungsten Opportunities Tungsten's high density, durability, and radiation-attenuation properties create opportunities for use in medical equipment, radiation shielding, imaging systems, and specialized healthcare applications. Growing investment in diagnostic imaging, radiation therapy, nuclear medicine, and other technologies requiring radiation protection can increase demand for tungsten-based components and shielding materials. Development of specialized tungsten alloys and composite materials can further expand its use in healthcare and radiation-protection applications.
01 Concentrated Global Supply and Geopolitical Restrictions Create Supply Security Challenges Developing alternative mines and processing capacity requires significant investment and lengthy permitting and construction periods, limiting the speed at which new supply can replace restricted material. In September 2026, reports indicated that availability of tungsten remained tightly constrained amid Chinese export restrictions and geopolitical tensions, prompting international buyers to seek more secure and diversified critical-mineral supply chains.
March 2026 AbbVie expanded its immunology portfolio with continued global development and commercialization activities for Skyrizi (risankizumab) and Rinvoq (upadacitinib), supporting advanced treatment options for psoriasis and other inflammatory skin disorders.
January 2026 Novartis expanded its dermatology portfolio with continued advancements for Cosentyx (secukinumab), including efforts to improve treatment access and patient outcomes in plaque psoriasis and related inflammatory diseases.
October 2025 Eli Lilly expanded its psoriasis treatment portfolio with continued growth of Taltz (ixekizumab) and development activities focused on IL-17-targeted therapies for chronic inflammatory skin conditions.
August 2025 Johnson & Johnson expanded its immunology and dermatology portfolio with continued development of Tremfya (guselkumab), supporting treatment options for moderate-to-severe plaque psoriasis and psoriatic arthritis.